Section 32

Endor Labs specializes in enhancing application security with a focus on managing open-source software dependencies. The company aids developers in integrating safe Open Source Software (OSS) to expedite development processes while minimizing time spent on security issues. Its Dependency Lifecycle Management Platform targets the vulnerabilities in software supply chain security caused by ungoverned use of open-source software within enterprises.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Sola Security is a cyber security company currently in Stealth mode.

Network Bio develops a platform that serves as a centralized repository for clinical and molecular data. This enables researchers to identify patterns and correlations, facilitating precision medicine approaches for common human diseases.

SandboxAQ specializes in developing advanced artificial intelligence and quantum technology products. The company integrates expertise from diverse fields to create Large Quantitative Models and AI sensing applications, focusing on practical solutions for industries such as financial services, healthcare, and telecommunications.

TollBit develops content monetization software that helps digital publishers license their content to AI bots and data scrapers while protecting the health of the content ecosystem. The software monitors scraped data, blocks unauthorized bot traffic, and enables publishers to manage licensing terms and revenue with scraping partners.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Basecamp Research is a pioneering biotechnology company specializing in mapping global genetic biodiversity for AI-driven design of biological systems. Utilizing its proprietary BaseGraph™ technology, the company creates tailored proteins for specific industrial, therapeutic, and diagnostic applications without relying on traditional directed evolution methods.

Nusano is a physics firm specializing in the production of radioisotopes, which are essential for diagnosing and treating cancer and various other medical conditions. The company has developed an advanced ion source and linear accelerator designed to overcome the limitations associated with traditional radioisotope manufacturing. By offering a diverse array of diagnostic and therapeutic radioisotopes produced without uranium, Nusano supports healthcare clients in the development of radiopharmaceuticals aimed at personalized cancer therapies. This innovative approach allows for the creation of these critical medical products at relatively lower costs, contributing to advancements in medical applications and improving patient outcomes.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

Puzzle Financial is a stealth mode SaaS startup focused on developing core accounting software designed to improve financial decision-making for startups. The platform aims to create a scalable foundation that supports fundraising, tax management, and real-time insights into overall business health. By transforming traditional accounting practices into a system of financial intelligence, Puzzle Financial enables startups to enhance their financial performance and gain greater trust and confidence in their financial operations.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Inceptive specializes in designing RNA molecules using large-scale deep learning algorithms, combined with high-throughput experiments. Their platform enables the creation of novel medicines and biotechnologies, making advanced biological software more accessible.

Endor Labs specializes in enhancing application security with a focus on managing open-source software dependencies. The company aids developers in integrating safe Open Source Software (OSS) to expedite development processes while minimizing time spent on security issues. Its Dependency Lifecycle Management Platform targets the vulnerabilities in software supply chain security caused by ungoverned use of open-source software within enterprises.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

Delve Bio is a biotechnology company that provides molecular insights to guide precision patient care, offering pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid to enable laboratories and clinicians to diagnose routine and rare infectious diseases with actionable results.

Function Oncology is a precision medicine company focused on transforming cancer treatment through its innovative CRISPR-powered personalized functional genomics platform. This platform enables the identification of therapeutic opportunities tailored to individual patients, allowing for a deeper understanding of cancer at a patient-specific level. By leveraging advanced genomic techniques, Function Oncology aims to develop targeted cancer therapies that address the unique characteristics of each patient's disease, ultimately advancing the future of cancer care.

Faro Health develops a cloud-based medical platform that standardizes, automates, and streamlines clinical trial processes. Its system handles administrative burdens, allowing clinical researchers to focus on critical decisions that drive clinical value.

Forward Networks, founded in 2013 and based in Palo Alto, California, specializes in developing software for network verification and automation. The company offers open-source tools like Beacon and Mininet to manage data centers and wide-area networks, along with Forward Essentials, a web application that provides real-time network state access, helping engineers and operators swiftly identify and resolve network issues. Their core product is an innovative platform delivering network visibility, policy verification, and change modeling, designed to minimize costly outages by enabling users to visualize complex networks, debug problems quickly, verify policy correctness, and predict network behavior before implementing changes in legacy, SDN, or hybrid environments.

Founded in 2016, MedCrypt specializes in cybersecurity software for medical devices. Its solutions ensure data security and protect against unauthorized access across a wide range of devices, from pacemakers to surgical robots.

Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.

Stairwell, Inc. is a cybersecurity company that specializes in developing software-as-a-service (SaaS) solutions designed to enhance threat detection and response capabilities for organizations. Founded in 2019 and headquartered in Palo Alto, California, Stairwell offers an innovative platform that automates threat analysis by treating all files as suspicious and preserving them as evidence. This approach allows security teams to conduct comprehensive compromise assessments rapidly, delivering timely reports on potential threats and their impact on the organization. The company's technology leverages artificial intelligence and machine learning to provide actionable insights, enabling security professionals to effectively track threats and their variants across their environments. Recognized as one of the most innovative companies of 2023 by Fast Company, Stairwell aims to empower security teams with advanced tools that enhance their ability to respond to cybersecurity incidents efficiently.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Spectral, established in 2020 and headquartered in New Rochelle, New York, specializes in developing an AI-driven platform for creating and deploying sophisticated smart contracts. This platform facilitates the generation of complex smart contracts using natural language, expediting development time and minimizing errors.

Inworld AI is an AI framework powering massive consumer applications. Inworld is funded by VCs including Lightspeed, Stanford University, Kleiner Perkins, Founders Fund, Section 32, M12, Intel Capital, CRV, Bitkraft, and Meta, as well as a team of all-star angels including corporate executives, top VC funds' partners, scouts, and industry veterans.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

BigHat Biosciences is a biotechnology company that develops an AI-guided platform for designing and characterizing antibodies and other therapeutic proteins. The platform combines a wet laboratory with artificial intelligence and machine learning to enable antibody discovery and optimization, helping drug developers create antibodies and novel biotherapeutic designs. It emphasizes multi-objective, data-driven workflows to improve safety, biophysical properties, and efficacy of antibody candidates. Founded in 2019 and based in San Carlos, California.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Swadesh is a digital banking platform for the Indian diaspora that enables customers to open accounts, invest, remit, and manage money in India from abroad, with cross-border features that simplify handling finances across India and abroad.

Manifold Biotechnologies, Inc. is a biotechnology company that specializes in developing platforms for the pharmacological measurement of various therapeutic protein variants. By integrating DNA technologies with machine learning, the company aims to create protein drugs that address challenging diseases. Manifold Bio's innovative approach includes a protein barcoding platform designed to enable multiplexed quantitation of protein therapeutics, thereby generating extensive data that enhances the drug development process. Founded in 2019 and located in Allston, Massachusetts, the company is focused on advancing measurement-driven design in the field of protein therapeutics.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Nirvana is an AI-native financial infrastructure shaping the future of Agentic DeFi. - Redefining DeFi with AI Agents – Nirvana builds AI frameworks for DEFAI agents to maximize capital efficiency - AI-Native On-Chain Protocols – Empowering DEFAI agents with AI-native protocols to autonomously launch innovative financial instruments and optimize strategies

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

SandboxAQ specializes in developing advanced artificial intelligence and quantum technology products. The company integrates expertise from diverse fields to create Large Quantitative Models and AI sensing applications, focusing on practical solutions for industries such as financial services, healthcare, and telecommunications.

Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

Cohere is a platform offering developers and businesses access to advanced natural language processing (NLP) capabilities powered by cutting-edge large language models. It enables the creation of machines that understand and interpret human language safely, benefiting various industries by enhancing comprehension capabilities and facilitating more personalized user experiences.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

Metaphysic develops software that enhances synthetic media creation. Its technology reconstructs low-resolution footage, generates natural-looking facial representations, and enables editing of expressions and facial features. This empowers content creators to leverage artificial intelligence in their work.

ONI specializes in super-resolution microscopy, making advanced imaging technology accessible to researchers worldwide. Its flagship product, the Nanoimager, offers easy access to techniques like dSTORM and PALM, enabling users to visualize molecules within living cells for enhanced biological research.

Nodexus is a biotech startup focused on providing innovative solutions for live single-cell isolation in the industrial, biopharma, clinical research, and academic sectors. The company commercializes the NX One platform, which features a low-cost, low-infrastructure hardware system and single-use disposable microfluidic cartridges. This platform is designed to enhance workflows related to gene editing, cell line and antibody development, and studies on tumor heterogeneity. By offering affordable automated cell isolation, Nodexus aims to accelerate biological research and make advanced technologies more accessible to a wider range of clients.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Verge Genomics is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for neurodegenerative diseases. The company is founded by experts in machine learning and neuroscience drug development who believe advances in computational genomics can reveal new targets and therapies. Verge Genomics' platform analyzes datasets of any size to identify targets and predict effective drugs, with the aim of delivering treatments that improve patient outcomes while reducing the cost and duration of pharmaceutical development.

Exai Bio is a next-generation liquid biopsy company that specializes in the early diagnosis of cancer through its proprietary RNA-based platform. This innovative platform focuses on the analysis of cell-free RNA profiles, particularly orphan non-coding RNA and small RNA sequences that are typically absent in normal tissues but prevalent in tumors. By leveraging advanced artificial intelligence and machine learning algorithms, Exai Bio provides clinical insights into cancer biology, enabling healthcare professionals to identify cancer accurately and at its earliest stages. The company's approach not only enhances diagnostic precision but also informs personalized care treatments for patients.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

MedArrive operates a SaaS platform that connects healthcare providers with patients in their homes. Its technology integrates clinical data into electronic medical records, facilitates communication, and manages billing. By utilizing an underutilized workforce of EMS professionals, MedArrive improves patient outcomes, fosters self-advocacy, reduces costs for payers and providers, and increases access to quality healthcare.

Founded in 2017, Mekonos specializes in the development of gene and cell therapies. The company designs integrated system-on-a-chip technology to create predictive models for discovery and development, and operates a proprietary cell-engineering platform based on scalable silicon technology.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

ScienceIO is a Massachusetts-based company established in 2019 by Gaurav Kaushik and Will Manidis. It specializes in developing a biomedical language platform that transforms unstructured biomedical data into contextualized information. The platform is designed to detect and extract biomedical terms, clinical variables, and medical codes from complex medical texts, thereby linking this information to create actionable insights. By connecting medical concepts, ScienceIO enables users to perform powerful queries and gain easy access to relevant medical data and alternatives, facilitating better decision-making in the biomedical field.

Founded in 2019, Gretel.ai is a San Diego-based company that specializes in developing software for data categorization and identification. It offers a multimodal synthetic data platform powered by advanced generative AI and privacy-enhancing technologies.

Wise Systems develops autonomous dispatch and routing software for last-mile delivery, using machine learning to automatically schedule, monitor, and adjust routes in real time to improve fleet efficiency and customer service. The platform analyzes orders, optimizes routes, tracks progress and ETAs, and evaluates driver performance, while providing a customer portal with real-time order visibility. It also includes Smart Reservation Management that lets customers select delivery dates and times. Serving industries such as food and beverage, parcel and courier, retail, field service, and other logistics sectors, Wise Systems processes millions of data points to deliver thousands of decisions daily. The company originated from MIT research and operates from Massachusetts, delivering scalable solutions that reduce mileage, boost fleet utilization, and minimize late deliveries.

Formation Bio is a biotechnology company dedicated to accelerating drug development and enhancing patient access to new treatments by reimagining clinical trials. The company has developed a platform that scales a network of clinical trial sites integrated within existing medical practices. By utilizing a roaming cohort of certified research coordinators and leveraging advanced software and data analytics, Formation Bio enables researchers to optimize their access to human subjects for various studies, including clinical trials and psychological research. This innovative approach aims to streamline the clinical trial process, ultimately facilitating faster delivery of new therapies to patients.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Cohere is a platform offering developers and businesses access to advanced natural language processing (NLP) capabilities powered by cutting-edge large language models. It enables the creation of machines that understand and interpret human language safely, benefiting various industries by enhancing comprehension capabilities and facilitating more personalized user experiences.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

ImmuneID is a precision immunology company that uses a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. The platform enables parallel, multiplexed, and unbiased analyses to develop therapeutics for autoimmunity, severe allergy, oncology, and infectious diseases, and helps researchers observe human immune responses throughout disease progression.

Primer Technologies develops software that uses machine learning and natural language processing to parse, collate, and analyze large multilingual document sets. Its platform reads documents, discovers insights, and automatically generates reports comparable to those produced by human analysts. The technology helps governments and corporations monitor and understand a wide range of information across languages, translating vast text data into actionable intelligence. Founded in 2014, Primer Technologies is based in San Francisco. The solution automates the analysis of substantial text datasets, enabling organizations to extract meaning from extensive stores of text data and accelerate investigations and decision-making.

Faro Health develops a cloud-based medical platform that standardizes, automates, and streamlines clinical trial processes. Its system handles administrative burdens, allowing clinical researchers to focus on critical decisions that drive clinical value.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.

Meatable is a Dutch food production company that specializes in creating cultured meat using stem cell technology. Founded in 2019, the company employs pluripotent stem cells to transform various types of cells into muscle or fat tissue, eliminating the need for animal slaughter. This process enables Meatable to produce sustainable, guilt-free meat without compromising taste and texture.

Miroculus develops and manufactures non-invasive tools for molecular data gathering, analysis, and interpretation. Its core technology is digital microfluidics, enabling automation and miniaturization of genomic protocols like NGS library prep and synthetic biology in a compact, cartridge-based system. The company serves academic institutions, pharmaceuticals, biotechnology, and diagnostics companies, empowering them to detect and monitor diseases at the molecular level.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

WithMe Health, LLC is a medication guidance company founded in 2018 and based in San Mateo, California. It offers a personalized medication guidance solution that tailors medication selection to individual needs, guiding members through their medication journey. By replacing traditional pharmacy benefit managers, WithMe Health provides an enhanced range of services that utilize modern technology and extensive datasets. The platform employs artificial intelligence to create customized medication experiences for employees and their families, focusing on proactive, adaptive, and engaging support. With an emphasis on optimizing health outcomes and value, WithMe Health aims to reduce costs for employers while aligning interests across the pharmaceutical value chain.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Founded in 2019, XOKind Inc. specializes in developing artificial intelligence software for the travel and leisure markets. Its AI agents learn user preferences from calendars, emails, photos, social media, and app interactions to simplify travel planning.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cradle Genomics, Inc. is a biotechnology company focused on advancing non-invasive prenatal testing (NIPT) through comprehensive fetal genetic analysis and pregnancy health screening solutions. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company aims to enhance the knowledge available to expectant parents. Cradle Genomics specializes in analyzing fetal cells collected during the first trimester, allowing for rapid and safe testing that poses no risk to the mother or developing fetus. By providing critical insights early in pregnancy, Cradle Genomics empowers women to make informed health decisions.